JP2019147775A - Patch - Google Patents

Abstract

To provide a patch having high flexibility and having excellent chemical resistance.SOLUTION: A patch has a first film, an agent layer, and a second film disposed between the first film and the agent layer. The first film has a styrenic elastomer. The second film has a polyethylene with a density of 0.94 g/cmor more. The styrenic elastomer is preferably a styrene-ethylene-butylene-styrene copolymer.SELECTED DRAWING: None

Description

The present invention relates to a patch. More specifically, the present invention relates to a patch having a drug layer.

Patches are preparations that are used by being applied to the skin. Examples include topical external preparations such as poultices (patients) for local action, and transdermal preparations for systemic action. It is done. In recent years, in addition to injections, oral preparations, ointments, etc., in addition to injections, oral preparations, ointments, etc., drug administration, ease of drug control, handling, and discontinuation of administration when adverse reactions occur Due to various advantages such as ease, a patch is attracting attention as a transdermal absorption preparation to be applied to the skin surface.

Examples of the patch include a structure in which a support and a drug layer are laminated. As the above-mentioned support, generally, a flexible material such as vinyl chloride resin, olefin resin, urethane, non-woven fabric, and net cloth is used. However, the drug may migrate from the drug layer to the support, and the support may swell or discolor. Various methods have been studied in order to suppress the transfer of the drug to the support. For example, a method of arranging another layer between the drug layer and the support has been studied (for example, Patent Document 1). 2).

In Patent Document 1, an adhesive layer is formed on one side of a composite film made of a resin composition obtained by blending 2 to 10 parts by weight of a styrene-ethylene-butylene-styrene copolymer with 100 parts by weight of a polyvinyl chloride-polyurethane composite. A polyalkylene terephthalate film is bonded to form a base sheet, a primer layer made of a saturated polyester resin is formed on the surface of the polyalkylene terephthalate film of the base sheet, and a drug is further applied on the primer layer. A skin patch sheet characterized by laminating an adhesive layer made of a styrene-diene-styrene block copolymer is disclosed.

In Patent Document 2, a base film layer having a thickness of 5 to 300 μm that is stretchable at room temperature, a vapor deposition layer having a thickness of 0.5 to 500 nm disposed on the base film layer, and a vapor deposition layer disposed on the vapor deposition layer. In addition, a support for a patch having a protective layer having a thickness of 5 μm or less is disclosed.

International Publication No. 1999/021537 JP 2009-249298 A

The support used for the patch may swell or change color depending on the drug contained in the drug layer. In addition, substances other than the drug contained in the support may adsorb the drug or may react with the drug, so that the effect of the patch cannot be fully expressed. Therefore, the support used for the patch is required to have chemical resistance that is not affected by the drug in addition to the flexibility to follow the movement of the skin.

In the said patent document 1, since the softness | flexibility of a polyalkylene terephthalate film is low, the softness | flexibility of a base material sheet may become inadequate. Further, as in Patent Document 2, in the method of forming a vapor deposition film on a support, the vapor deposition film does not follow the expansion and contraction of the support, cracks may be generated, and sufficient chemical resistance may not be obtained. It was. In addition, the method of forming the deposited film has a problem that it is expensive.

The present invention has been made in view of the above situation, and an object thereof is to provide a patch having high flexibility and excellent chemical resistance.

The inventor of the present invention paid attention to the use of a film containing a styrene-based elastomer as the support for the patch, thereby obtaining elasticity and flexibility suitable for the support for the patch. Furthermore, by disposing a film containing polyethylene having a density of 0.94 g / cm ³ or more between the film containing the styrenic elastomer and the drug layer, the drug layer is maintained while maintaining appropriate flexibility. The present invention has been completed by finding that it is possible to suppress the transfer of a drug to the film containing the styrene-based elastomer.

The patch of the present invention comprises a first film, a drug layer, and a second film disposed between the first film and the drug layer, wherein the first film is a styrenic An elastomer is contained, and the second film contains polyethylene having a density of 0.94 g / cm ³ or more.

The styrenic elastomer is preferably a styrene-ethylene-butylene-styrene copolymer.

The total of the thickness of the first film and the thickness of the second film is preferably 10 to 140 μm.

The patch of the present invention has high flexibility and excellent chemical resistance.

The patch of the present invention comprises a first film, a drug layer, and a second film disposed between the first film and the drug layer, wherein the first film is a styrenic An elastomer is contained, and the second film contains polyethylene having a density of 0.94 g / cm ³ or more.

<First film>
The first film contains a styrene elastomer. The styrene-based elastomer widely includes elastomers obtained by copolymerizing styrene and other polymerizable monomers. The styrene elastomer includes a hard segment made of polystyrene and a soft segment made of the other polymerizable monomer. Since the styrenic elastomer contains the hard segment, it can impart appropriate elasticity to the support of the patch. In addition, a monomer having a hard segment made of polystyrene having a bulky molecular structure is polymerized, and the bulky molecular structure is uniformly dispersed in the first film, so that a medicinal component enters the first film. Can be prevented. Since the soft segment is included, moderate flexibility can be imparted.

The other polymerizable monomer is not particularly limited as long as it is a monomer that can be copolymerized with styrene, and examples thereof include diene compounds such as butadiene, isoprene and chloroprene, olefins such as ethylene, propylene, butene and hexene, ( Examples thereof include (meth) acrylic acid and (meth) acrylic acid esters. These may be used alone or in combination of two or more.

The styrene elastomer is preferably a styrene-olefin block copolymer from the viewpoint of excellent dimensional stability. The styrene-olefin block copolymer has a polystyrene block phase at both ends of one molecule and an olefin elastomer phase introduced into an intermediate phase.

Examples of the styrene-olefin block copolymer include a styrene-butadiene-styrene copolymer (SBS) whose intermediate phase is polybutadiene, and a styrene-isoprene-styrene copolymer (SIS) whose intermediate phase is polyisoprene. And styrene-ethylene-butylene-styrene copolymer (SEBS) and styrene-ethylene-propylene-styrene copolymer (SEPS), which are hydrogenated polyolefins in the intermediate phase. In addition to these, styrene-ethylene / propylene diblock copolymer (SEP), hydrogenated butadiene rubber (HSBR), and the like can also be used. These may be used alone or in combination of two or more.

Especially, it is preferable that the said styrene-type elastomer is a styrene-ethylene-butylene-styrene copolymer. By using SEBS for the first film, excellent flexibility can be obtained. In addition, since the SEBS has many side chains, it is considered that the drug component can be prevented from entering the first film while providing appropriate elasticity. Furthermore, since SEBS does not contain a double bond, it has excellent weather resistance and heat resistance. Examples of the SEBS include AR-850C, AR-815C (both manufactured by Aron Kasei Co., Ltd.), Lavalon SS6302C (manufactured by Mitsubishi Plastics Co., Ltd.), and the like.

The melt flow rate (MFR) of the styrene elastomer is preferably 0.01 to 10 g / 10 min. The MFR of the styrene elastomer can be measured by a method based on ISO 1133, 230 ° C. × 21.2 N).

The first film is a film containing the styrene elastomer as a main component. It is preferable that content of the said styrene-type elastomer with respect to the said 1st whole film is 55 weight% or more. If the content of the styrenic elastomer is less than 55% by weight, flexibility suitable for the support of the patch may not be obtained. The content of the styrenic elastomer is more preferably 60% by weight or more, and still more preferably 70% by weight or more. Although the upper limit of content of the said styrene-type elastomer is not specifically limited, For example, it is 90 weight%.

The first film further includes polyethylene such as low density polyethylene (LDPE) and linear low density polyethylene (LLDPE), ethylene-vinyl acetate copolymer (EVA), thermoplastic elastomer (TPE), PP and the like. You may contain.

The first film may further contain various additives. Examples of the additive include a lubricant, an antioxidant, a heat stabilizer, an ultraviolet absorber, a light stabilizer, a colorant, a modifier, a flame retardant, an antistatic agent, a reinforcing agent, an antifogging agent, a filler, Examples include diluents and fungicides.

The thickness of the first film is preferably 5 to 100 μm. When the thickness of the first film is less than 5 μm or exceeds 100 μm, the flexibility and texture necessary for the patch may not be obtained. A more preferable lower limit of the thickness of the first film is 15 μm, and a more preferable upper limit is 70 μm. The thickness of the first film is an average value measured at 7 points using a dial gauge of 5 mmφ.

<Second film>
The second film is disposed between the first film and the drug layer. By arrange | positioning a 2nd film, it can suppress that a chemical | medical agent transfers to said 1st film from said chemical | medical agent layer, and said 1st film swells or colors.

The second film contains polyethylene having a density of 0.94 g / cm ³ or more. Hereinafter, polyethylene having a density of 0.94 g / cm ³ or more is also referred to as “High Density Polyethylene” (HDPE: High Density Polyethylene). When the second film contains high-density polyethylene, the migration of the drug from the drug layer to the first film can be sufficiently suppressed, and the chemical resistance can be improved. Moreover, the rigidity of a film can be improved and it can be made hard to tear. When the density of the polyethylene is less than 0.94 g / cm ³ , the migration of the drug from the drug layer to the first film cannot be sufficiently suppressed, and the first film swells or colors. . The upper limit of the density of the high density polyethylene is not particularly limited, but is preferably 1.0 g / cm ^3, more preferably 0.97 g / cm ^3. When the density of the high-density polyethylene exceeds 0.97 g / cm ³ , the rigidity of the second film is increased, and the brittleness may be brittle. The density of the polyethylene is a density measured by any one of the pycnometer method, the underwater displacement method, the flotation method, and the density gradient tube method in accordance with ISO 1183.

The MFR of the high density polyethylene is preferably 2.0 g / 10 min or less. When the melt flow rate exceeds 2.0 g / 10 minutes, the melt viscosity of the resin is low, and the calender roll and the resin composition are in close contact with each other, making it difficult to take off from the calender roll. May become difficult. When the second film is formed by extrusion molding, the MFR of the high-density polyethylene is preferably 5.0 g / 10 min or less. If the MFR exceeds 5.0 g / 10 min, the viscosity of the resin is too low, so that the film cannot be formed by extrusion molding under appropriate processing conditions. Although the minimum of MFR of the said high density polyethylene is not specifically limited, For example, it is 0.05 g / 10min. A more preferable lower limit of MFR of the high-density polyethylene is 1.0 g / 10 minutes, and a more preferable lower limit is 1.5 g / 10 minutes. MFR of the said high density polyethylene can be measured by the method based on JISK6922-2.

The second film is a film mainly composed of the high-density polyethylene. The content of the high-density polyethylene with respect to the entire second film is preferably 55% by weight or more. If the content of the high-density polyethylene is less than 55% by weight, sufficient chemical resistance may not be obtained.

The high-density polyethylene is not particularly limited as long as the density is 0.94 g / cm ³ or more, but may be a homopolymer of ethylene or a copolymer of ethylene and α-olefin. Good. Further, it may be polymerized with a metallocene catalyst, Ziegler catalyst, Phillips catalyst or the like. Examples of the polyethylene having a density of 0.94 g / cm ³ or more include T4005 (density: 0.949 g / cm ³ ) and T8150 (density: 0.96 g / cm ³ ) manufactured by Keiyo Polyethylene Co., Ltd.

The second film further includes polyethylene such as low density polyethylene (LDPE) and linear low density polyethylene (LLDPE), ethylene-vinyl acetate copolymer (EVA), thermoplastic elastomer (TPE), PP and the like. You may contain.

The second film may further contain various additives. As said additive, the thing similar to said 1st film is mentioned.

The thickness of the second film is preferably 5 to 40 μm. If the thickness of the second film is less than 5 μm, chemical resistance may not be exhibited. On the other hand, when the thickness of the second film exceeds 40 μm, the flexibility and texture necessary for the patch may not be obtained. A more preferable lower limit of the thickness of the second film is 8 μm, and a more preferable upper limit is 25 μm. The thickness of the second film can be measured in the same manner as the thickness of the first film.

A laminate (hereinafter also referred to as a laminate) of the first film and the second film has a role as a support for the patch. The total of the thickness of the first film and the thickness of the second film is preferably 10 to 140 μm. When the total thickness is less than 10 μm, there is a possibility that sufficient strength cannot be exhibited as a support for the patch. On the other hand, when the total thickness exceeds 140 μm, flexibility as a support may be reduced. A more preferable lower limit of the total thickness is 20 μm, and a more preferable upper limit is 100 μm.

The thickness of the first film is preferably equal to or greater than the thickness of the second film. The ratio of the thickness of the first film to the thickness of the second film is preferably 1: 1 to 3: 1, for example.

The laminate preferably has an elongation of 80% or more, a 50% modulus of 2 to 50 N / 19 mm, and a breaking strength of 5 to 100 N / 19 mm. The elongation, 50% modulus, and breaking strength preferably satisfy the above numerical ranges in both the flow direction (MD: Machine Direction) and the width direction (CD: Cross Machine Direction) of the laminate. In the present specification, the elongation, 50% modulus, and breaking strength are determined in accordance with JIS Z 0237, each of a strip-like piece having a width of 19 mm × a length of 180 mm, a chuck interval of 50 mm, and a distance between marked lines of 100 mm. The value measured under the conditions of a tensile speed of 300 mm / min and a temperature of 23 ° C. ± 2 ° C.

If the elongation is less than 80%, it may not be able to follow the movement of the skin when applied to the skin. A more preferable lower limit of the elongation is 100%. Although the upper limit of the said elongation is not specifically limited, For example, it is 1000%. The said elongation is represented by the elongation rate of following formula (1). In the following formula (1), La is the length of the test piece before the tensile test is performed, and Lb is the length of the test piece when the test piece is broken in the tensile test.
Elongation rate (%) = {(Lb−La) / La} × 100 (1)

If the 50% modulus is less than 2 N / 19 mm, the stiffness of the laminate may be reduced, making it difficult to handle. On the other hand, if the 50% modulus exceeds 50 N / 19 mm, the stiffness of the laminated body becomes strong and the usability may be lowered. The more preferable lower limit of the 50% modulus is 5 N / 19 mm, and the more preferable upper limit is 40 N / 19 mm.

If the breaking strength is less than 5 N / 19 mm, the strength of the laminate may be insufficient. If the breaking strength exceeds 100 N / 19 mm, the stiffness of the laminate is increased, and the usability may be lowered. A more preferable lower limit of the breaking strength is 8 N / 19 mm, and a more preferable upper limit is 70 N / 19 mm.

Although the manufacturing method of said 1st film and said 2nd film is not specifically limited, For example, a calender molding method, an extrusion molding method, and a cast molding method can be used, and calender molding method or extrusion molding method is especially suitable. It is. The laminate is obtained by laminating, for example, by providing an adhesive layer between the first film and the second film.

Said 2nd film may have a primer layer, an adhesive layer, etc. between the chemical | medical agent layers mentioned later, and may contact a chemical | medical agent layer. By having a primer layer, a pressure-sensitive adhesive layer, etc. between the second film and the drug layer, the adhesion between the second film and the drug layer can be enhanced. When the second film and the drug layer are in contact with each other, the drug moves from the drug layer to the first film, and the first film is more effectively suppressed from swelling or coloring. be able to.

<Drug layer>
The drug layer is a layer containing a drug. The drug may be a systemic action drug or a local action drug. Examples of the drug include indomethacin, ferbinac, ketoprofen, flurbiprofen, salicylic acid, glycol salicylate, methyl salicylate, L-menthol, camphor, peppermint oil, thymol, horse chestnut extract, arnica tincture, pepper extract, diphenhydramine, glycyrrhetin Examples thereof include acid, crotamiton, isopropylmethylphenyl, nitroglycerin, isosorbide nitrate, tulobuterol, fentanyl, estradiol, steroid, and nicotine. These drugs may be used alone or in combination of two or more.

The patch of the present invention can be used as, for example, a smoking cessation aid (Nichicon patch), an anti-inflammatory analgesic (a poultice, a plaster formulation) or the like containing nicotine as a drug. When the patch of the present invention is used as a smoking cessation aid, the content of the drug varies depending on the treatment stage, but is, for example, about 15 to 80 mg per preparation. The anti-inflammatory analgesic agent contains indomethacin, ferbinac, ketoprofen, flurbiprofen, salicylic acid, glycol salicylate, methyl salicylate, L-menthol, camphor, peppermint oil, thymol, horse chestnut extract, arnica tincture, etc. Things.

The drug layer is preferably a pressure-sensitive adhesive layer containing a drug. The said adhesive layer consists of an adhesive composition containing the said chemical | medical agent and an adhesive. As said adhesive layer, the layer which consists of an acrylic adhesive, a rubber adhesive, and a silicone adhesive is mentioned, for example. Here, each adhesive may be a solvent type, an emulsion type, or a hot melt type.

The method for forming the pressure-sensitive adhesive layer containing the drug is not particularly limited. For example, the pressure-sensitive adhesive composition is prepared by mixing the drug and the pressure-sensitive adhesive, and the pressure-sensitive adhesive composition is mixed with the second film. A direct coating method is mentioned. After the pressure-sensitive adhesive composition is applied to a release paper, it may be bonded to the second film. Moreover, after processing the said adhesive composition into a sheet form, you may bond together.

The drug layer may be a drug storage layer containing a drug. In this case, the patch of the present invention may further have a pressure-sensitive adhesive layer on the surface of the drug layer opposite to the second film. The drug layer may be constituted by the drug storage layer and a coating layer covering the drug storage layer. The coating layer is, for example, a layer that adjusts the release rate of the drug.

Another layer may be further provided between the first film and the second film. For example, in order to improve the adhesion between the first film and the second film, a primer layer, an adhesive layer, and the like may be provided.

The patch of the present invention may be subjected to a surface treatment on the surface of the second film on the drug layer side. Thereby, the improvement of the adhesiveness of said 2nd film and said chemical | medical agent layer, etc. can be aimed at. Examples of the surface treatment include conventionally known surface treatments such as corona treatment, plasma treatment, flame treatment, and UV treatment. Among these, corona treatment is common in consideration of the width of the film (which can be widened) and productivity.

The first film may be embossed on the surface opposite to the second film. The first film may have a printed layer, a surface layer, and the like on the surface opposite to the second film.

The printed layer may cover the entire surface of the first film or may partially cover it. For example, when the printing layer has a planar shape corresponding to an arbitrary pattern or information, the printing layer partially covers the surface of the first film.

Although the printing method for forming the said printing layer is not specifically limited, Inkjet printing, gravure printing, etc. can be used. Gravure printing is suitable for printing a continuous pattern over a wide area. As the ink used for the print layer, for example, one-component curable ink, two-component curable ink, ultraviolet curable ink, or the like can be used.

EXAMPLES Hereinafter, although an Example is hung up and demonstrated in more detail about this invention, this invention is not limited only to these Examples.

<Combination raw material>
The raw materials used for producing the following Examples and Comparative Examples are as follows.
(1) Styrene-ethylene-butylene-styrene copolymer (SEBS)
SEBS-1: AR-850C (Aron Kasei Co., Ltd.)
SEBS-2: Lavalon SS6302C (Mitsubishi Resin Co., Ltd.)
SEBS-3: AR-815C (Aron Kasei Co., Ltd.)
(2) High density polyethylene (HDPE)
HDPE-1: T4005 (manufactured by Keiyo Polyethylene Corporation)
HDPE-2: Evolue (registered trademark) H SP3505 (manufactured by Prime Polymer Co., Ltd.)
(3) Vinyl chloride resin (PVC)
Kane Vinyl (registered trademark) S1003 (manufactured by Kaneka Corporation)
(4) Linear low density polyethylene (LLDPE)
Evolue (registered trademark) SP0540 (manufactured by Prime Polymer Co., Ltd.)
(5) Polyurethane (PU)
Heimlen (registered trademark) Y-210B (manufactured by Dainichi Seika Kogyo Co., Ltd.)

<Production of support>
(Support A)
A resin composition containing 60 parts by weight of the SEBS-1, 20 parts by weight of the HDPE-1 and 2 parts by weight of ADK STAB LS-16 (manufactured by ADEKA Corporation) as a lubricant was prepared, and the resin composition was extruded. By the method, it was molded into a film having a thickness of 20 μm to produce a first film.

The resin composition containing only the HDPE-1 was molded into a film having a thickness of 10 μm by the extrusion molding method in the same manner as the first film to produce a second film.

The surface of the first film is subjected to corona treatment, the surface of the first film subjected to corona treatment and the second film coated with an adhesive are bonded together by dry lamination, and the support A is attached. Produced. At this time, lamination was performed such that the flow direction (MD) and the width direction (CD) of the first and second films coincided. The thickness of the first film and the thickness of the second film were measured using an average value measured at 7 points using a 5 mmφ dial gauge.

(Supports B to J)
As shown in Table 1 below, Supports B to J were prepared in the same manner as Support A, except that the composition and / or thickness of the first film and / or the second film was changed. . In addition, support body DG produced the 1st film using the mixing | blending raw material shown in following Table 1, and did not laminate | stack the 2nd film. The thicknesses of the first film and the second film were measured in the same manner as the support A.

<Preparation of patch>
Each of the above supports was cut into a width of 15 mm and a length of 15 mm, and as shown in Table 1 below, the support and a nicotine preparation (Nicotine® (registered trademark) 20, manufactured by Novartis Pharma Co., Ltd.) were laminated and carried out. Patches of Examples 1 to 3 and Comparative Examples 1 to 7 were prepared. In Examples 1 to 3 and Comparative Examples 5 to 7, the release liner was peeled from the nicotine preparation, and the nicotine preparation pressure-sensitive adhesive layer and the second film were bonded together. In Comparative Examples 1-4, it bonded together so that the 1st film and the adhesive layer of a nicotine formulation might contact.

[Evaluation test]
The following methods were used to measure (1) 50% modulus, (2) breaking strength, and (3) elongation of the support. Furthermore, (4) chemical resistance was evaluated about the patch of the said Example and the comparative example.

(1) Each of the supports obtained with a modulus of 50% was cut into 19 mm × 180 mm to prepare test pieces. For each support, the test piece for MD measurement cut out so that the long side of the test piece is in the flow direction (MD) of the support, and the long side of the test piece is in the width direction (CD) of the support A cut CD test piece was prepared. The 50% modulus was measured by using an automatic recording type tensile tester to measure the load when the MD measurement test piece and the CD measurement test piece were each stretched 50% in the longitudinal direction of the test piece. The 50% modulus, the following breaking strength and the following elongation were measured by a method based on JIS Z 0237.

Each test piece was sandwiched between chucks, and each test piece was elongated in the longitudinal direction under the following conditions. When the 50% modulus in the flow direction and the width direction was 2 to 50 N / 19 mm, the support was judged to have flexibility suitable for the patch.
Measurement temperature: 23 ° C ± 2 ° C
Distance between marked lines: 100 mm
Distance between chucks: 50mm
Tensile speed: 300 mm / min

(2) Breaking strength Under the same conditions as the above 50% modulus measurement, each test piece was stretched and the strength when it was broken was measured. When the breaking strength in the flow direction and the width direction was 5 to 100 N / 19 mm, the support was judged to have flexibility suitable for the patch.

(3) Elongation Under the same conditions as the measurement of the 50% modulus, each test piece was elongated, and the elongation rate when it was broken was defined as “elongation”. The extension ratio was calculated by the following formula (1). In the following formula (1), La is the length of the test piece before the tensile test is performed, and Lb is the length of the test piece when the test piece is broken in the tensile test. When the elongation in the flow direction and the width direction was 140% or more, the support was judged to have flexibility suitable for the patch.
Elongation rate (%) = {(Lb−La) / La} × 100 (1)

(4) Chemical resistance The patches of Examples and Comparative Examples were placed in a bag made of an aluminum / polyethylene film laminate and sealed by heat sealing. This was left in an oven at 60 ° C. for 2 days. Thereafter, each patch was taken out, the nicotine preparation was peeled from the support, and the surface state of the support in contact with the nicotine preparation was visually observed. The surface state of the support was evaluated according to the following evaluation criteria.
3: No change in surface condition (good without wrinkles and discoloration)
2: There is a slight change in the surface condition (wrinkles and discoloration occurred slightly)
1: There is a significant change in surface condition (wrinkles and discoloration are significant)

Examples 1 to 3 were excellent in flexibility and excellent in chemical resistance. On the other hand, Comparative Examples 1 to 4 having no second film have insufficient chemical resistance, and significant changes such as wrinkles and discoloration are observed on the surface of the first film that was in contact with the nicotine preparation. It was. In Comparative Example 5 using the second film containing polyethylene having a density of less than 0.94 g / cm ³ , a significant change was observed on the surface of the first film in contact with the nicotine preparation. Although not as much as Comparative Example 5, a change was observed on the surface of the first film. Comparative Example 7 in which the composition of the first film and the second film was exchanged was not as large as Comparative Examples 1 to 4, but sufficient chemical properties were not obtained, and the surface that was in contact with the nicotine preparation of the first film There was a change.

Claims (3)

A first film, a drug layer, and a second film disposed between the first film and the drug layer,
The first film contains a styrenic elastomer,
The patch, wherein the second film contains polyethylene having a density of 0.94 g / cm ³ or more. The patch according to claim 1, wherein the styrene elastomer is a styrene-ethylene-butylene-styrene copolymer. The patch according to claim 1 or 2, wherein the total thickness of the first film and the thickness of the second film is 10 to 140 µm.